Taysha Gene Therapies (TSHA) has drawn fresh attention after completing patient dosing in its pivotal REVEAL trial of TSHA-102 for Rett syndrome and sharing longer-term safety and functional outcome data.

The Rett data release has arrived alongside a sharp shift in how the market prices Taysha Gene Therapies, with a 30 day share price return of 16.94% and a year to date share price return of 22.29%. The 1 year total shareholder return of 157.83% and very large 3 year total shareholder return reflect how sentiment has evolved around the company’s pipeline and risk profile over time.

If the Rett update has you thinking more broadly about healthcare opportunities, it could be worth scanning other potential high growth candidates through our healthcare focused screener, including 38 healthcare AI stocks

With Taysha Gene Therapies now valued at about $1.84b and trading at $6.42, yet sitting at a sizeable implied discount to analyst targets and intrinsic estimates, is there still mispricing here or is the market already counting on future growth?

Most Popular Narrative: 47.5% Undervalued

The most followed narrative currently pegs Taysha Gene Therapies at a fair value of about $12.23 per share, compared with the latest close at $6.42, framing a wide gap that hinges on aggressive future assumptions.

Progress in the clinical development of TSHA-102, particularly moving towards the pivotal phase of the REVEAL trials with promising safety and efficacy data, could enhance investor confidence and potentially lead to future revenue growth once regulatory approval is achieved. Ongoing constructive discussions with the FDA about the regulatory pathway for TSHA-102, including potential expedited approval mechanisms like the RMAT designation, may accelerate product approval and market entry, thereby impacting future earnings positively.

Want to see what has to happen for that fair value to hold? Analysts are banking on rapid revenue expansion, a sharp margin turnaround and a premium earnings multiple. The full narrative spells out exactly how those pieces fit together.

Result: Fair Value of $12.23 (UNDERVALUED)

However, investors in Taysha Gene Therapies still face meaningful uncertainties, including the risk of regulatory delays and ongoing losses of about $129.9 million.

Next Steps

Curious whether the current optimism around Taysha Gene Therapies really outweighs the concerns? Act quickly, review the latest data and weigh both sides with the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Taysha Gene Therapies?

If Taysha Gene Therapies has sharpened your focus, do not stop here. Widen your watchlist with fresh ideas that match your risk tolerance and investing style.

• Target potential mispricings by scanning companies that look attractively valued using the 45 high quality undervalued stocks.
• Strengthen your income stream by checking out companies with robust yields and payout histories through the 8 dividend fortresses.
• Focus on resilience and capital preservation by reviewing 66 resilient stocks with low risk scores before the next wave of opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.